This dual-targeting approach is exemplified by MiNK-215, an allogeneic IL-15-armored FAP-targeting CAR-iNKT therapy that demonstrated remarkable efficacy in models of treatment-resistant microsatellite-stable colorectal cancer liver metastases by eliminating FAP+ cancer-associated fibroblasts and promoting T cell infiltration and activation in tumors refractory to checkpoint blockade (22, 100, 101). This evidence concerns the gene FAP and colorectal cancer.